TABLE OF CONTENTS

Volume 3, Issue 3 (June 2003)

Top

Editorial

Editorial: Hidden Diamonds

Brian Smith

J Med Market 3: 172-173; doi:10.1057/palgrave.jmm.5040116

Top

Papers

Defining, justifying and implementing the Balanced Scorecard in the National Health Service

Zoe Radnor and Bill Lovell

J Med Market 3: 174-188; doi:10.1057/palgrave.jmm.5040117

Strategic responses of pharmaceutical companies and healthcare organisations to maintain competitive advantage in the cataract market

Georgios Labiris, Georgios Papadopoulis and Andreas Petounis

J Med Market 3: 189-193; doi:10.1057/palgrave.jmm.5040118

Top

Miscellaneous

Guest Editorial: Defending value and maximising profitability of innovative pharmaceuticals over their entire life cycles

Lindsay Bruce

J Med Market 3: 195-197; doi:10.1057/palgrave.jmm.5040119

Top

Papers

Generic pharmaceutical cases: A review of 2002's cases and 'long arm' relief — the current position

Lindsay Bruce

J Med Market 3: 199-203; doi:10.1057/palgrave.jmm.5040120

Common mistakes that undermine patent protection and how to avoid them

Mike Hutchins

J Med Market 3: 204-211; doi:10.1057/palgrave.jmm.5040121

Using interlocking additional early stage patents to improve and extend patent protection

Mike Hutchins

J Med Market 3: 212-215; doi:10.1057/palgrave.jmm.5040122

Global patent enforcement

Nigel Stoate

J Med Market 3: 216-219; doi:10.1057/palgrave.jmm.5040123

The latest thinking on best strategies for use of supplementary certificates

Julian Hitchcock and Bülent Tugal

J Med Market 3: 220-225; doi:10.1057/palgrave.jmm.5040124

The art of using secondary patents to improve protection

Michael Burdon and Kristie Sloper

J Med Market 3: 226-238; doi:10.1057/palgrave.jmm.5040125

EU enlargement, the Bolar exemption and parallel imports: The consequences for market exclusivity

Nigel Stoate

J Med Market 3: 239-244; doi:10.1057/palgrave.jmm.5040126

Pricing policies to handle patent loss or expiry

Adam Barak and Geoffrey Wilson

J Med Market 3: 245-249; doi:10.1057/palgrave.jmm.5040127

Commercial strategies for implementation of branding and OTC switching policies

Richard Eggleston

J Med Market 3: 250-254; doi:10.1057/palgrave.jmm.5040128

Extra navigation

.
ADVERTISEMENT